文献速递糖尿病骨质疏松与钙磷/甲状旁腺

多因素强化干预对2型糖尿病患者骨折的影响:J-DOIT3研究亚分析

Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本亚分析基于日本多中心开放标签随机平行组J-DOIT3研究,评估强化多因素干预(血糖、血压、血脂目标更严格)与常规治疗对2型糖尿病患者骨折发生率的影响。结果显示两组骨折累积发生率无显著差异(HR 1.15;95%CI 0.91-1.47;P=0.241)。男性基线吸烟史与骨折发生显著相关,女性骨折发生与基线FRAX评分及随机化后1年吡格列酮使用相关。

要点

  • 强化多因素干预未增加2型糖尿病患者骨折风险
  • 男性基线吸烟史与骨折发生显著相关(HR 1.96)
  • 女性基线FRAX评分及1年时吡格列酮使用与骨折发生相关

核心结论

  • 强化多因素干预可在不增加骨折风险的情况下实施于2型糖尿病患者
  • 男性有吸烟史者骨折风险升高
  • 女性骨折风险可由FRAX评分预测,且与吡格列酮使用独立相关

研究设计与样本

  • J-DOIT3研究为日本多中心、开放标签、随机、平行组试验
  • 2型糖尿病患者随机分配至常规治疗组或强化治疗组
  • 本分析针对研究中报告的不良事件中的骨折事件进行识别与分析

主要发现

  • 常规治疗组与强化治疗组骨折累积发生率无差异(HR 1.15;95%CI 0.91-1.47;P=0.241)
  • 男性基线吸烟史与骨折发生显著相关(HR 1.96;95%CI 1.04-3.07;P=0.038)
  • 女性基线FRAX评分(%/10年)与骨折发生相关(HR 1.04;95%CI 1.02-1.07;P<0.001)
  • 女性随机化后1年吡格列酮使用与骨折发生相关(HR 1.59;95%CI 1.06-2.38;P=0.025)

关键数值与推荐

  • 常规治疗目标:HbA1c<6.9%、血压<130/80 mm Hg、LDL胆固醇<120mg/dL
  • 强化治疗目标:HbA1c<6.2%、血压<120/75 mm Hg、LDL胆固醇<80mg/dL
  • 试验注册号:ClinicalTrials.gov NCT00300976

临床怎么用

  • 对2型糖尿病患者实施强化多因素干预时无需因骨折风险而顾虑
  • 男性患者应关注吸烟史以评估骨折风险
  • 女性患者可参考基线FRAX评分评估骨折风险
  • 女性使用吡格列酮时需注意骨折风险

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the effects of an intensified multifactorial intervention and patient characteristics on the incidence of fractures comorbid with type 2 diabetes. METHODS: Fracture events were identified and analyzed among adverse events reported in the J-DOIT3 study, a multicenter, open-label, randomized, parallel-group trial that was conducted in Japan, in which patients with type 2 diabetes were randomly assigned to receive conventional therapy for glucose, blood pressure, and lipids (targets: HbA1c < 6.9%, blood pressure <130/80 mm Hg, LDL-cholesterol <120mg/dL) or intensive therapy (HbA1c < 6.2%, blood pressure <120/75 mm Hg, LDL-cholesterol <80mg/dL) (ClinicalTrials.gov registration no. NCT00300976). RESULTS: The cumulative incidence of fractures did not differ between those receiving conventional therapy and those receiving intensive therapy (hazard ratio (HR) 1.15; 95% CI, 0.91-1.47; P = 0.241). Among the potential risk factors, only history of smoking at baseline was significantly associated with the incidence of fractures in men (HR 1.96; 95% CI, 1.04-3.07; P = 0.038). In contrast, the incidence of fractures in women was associated with the FRAX score [%/10 years] at baseline (HR 1.04; 95% CI, 1.02-1.07; P < 0.001) and administration of pioglitazone at 1 year after randomization (HR 1.59; 95% CI, 1.06-2.38; P = 0.025). CONCLUSIONS: Intensified multifactorial intervention may be implemented without increasing the fracture risk in patients with type 2 diabetes. The fracture risk is elevated in those with a history of smoking in men, whereas it is predicted by the FRAX score and is independently elevated with administration of pioglitazone in women.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sasako T, Ueki K, Miyake K, et al. Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study. J Clin Endocrinol Metab. 2021. PMID: 33491087. doi:10.1210/clinem/dgab013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。